"10.1371_journal.pone.0103835","plos one","2014-08-01T00:00:00Z","Nada M S Al-Saffar; Lynley V Marshall; L Elizabeth Jackson; Geetha Balarajah; Thomas R Eykyn; Alice Agliano; Paul A Clarke; Chris Jones; Paul Workman; Andrew D J Pearson; Martin O Leach","Cancer Research UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Division of Molecular Pathology, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Division of Cancer Therapeutics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Division of Clinical Studies. The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Division of Imaging Sciences and Biomedical Engineering, Kings College London, St Thomas Hospital, London, United Kingdom; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom","Conceived and designed the experiments: NMSA LVM AA PAC CJ PW ADJP MOL. Performed the experiments: NMSA LVM LEJ GB TRE AA. Analyzed the data: NMSA LVM LEJ GB TRE AA. Contributed reagents/materials/analysis tools: NMSA LVM LEJ GB TRE AA PAC CJ PW ADJP MOL. Contributed to the writing of the manuscript: NMSA LVM LEJ GB TRE AA PAC CJ PW ADJP MOL.","The authors of this manuscript have the following competing interests: NMSA, LEJ, GB, TRE, AA, PAC, CJ, ADJP, PW and MOL are employees of the Institute of Cancer Research, which has a commercial interest in the development of PI3K inhibitors, and operates a Rewards to Inventors scheme. PW and PAC have been involved in a commercial collaboration with Yamanouchi (now Astellas Pharma) and with Piramed Pharma and intellectual property arising from the program has been licensed to Genentech. Genentech and Piramed Pharma were acquired by Roche. PW was a founder of, consultant to, and Scientific Advisory Board member of Piramed Pharma (acquired by Roche); was a founder of, consultant to and Scientific Advisory Board and Main Board member of Chroma Therapeutics; is a Consultant/Scientific Advisory Board member to Nextech Ventures, Astex Pharmaceuticals and Wilex Oncology; and was formerly an employee of AstraZeneca. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","08","Nada M S Al-Saffar","NMSAS",11,TRUE,8,6,6,NA,TRUE,TRUE,FALSE,0,NA,FALSE
